Myelopeptides and their therapeutic use — US6469137B1
Patent disclosure · 2002
- What the patent describes
- Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
- Reported evidence
- MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.
MP-4 leukemia-cell differentiation · Approximately 60% mature monocyte/macrophage forms reported among the examined cells · In-vitro morphology endpoint, not a leukemia remission rate
Reported patent results
Reported findings
MP-4 induced a differentiation-like phenotype in leukemia cells; the individual myelopeptides did not act uniformly across the assays.
Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
Population or model Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MP-4 leukemia-cell differentiation | Approximately 60% mature monocyte/macrophage forms reported among the examined cells | In-vitro morphology endpoint, not a leukemia remission rate |
| Short-term viability | No visible damage reported for the tested MP-3–MP-6 cell-culture conditions | A limited cell assay, not clinical or long-term safety · 24-hour observation |
Cell differentiation, assay response and lack of visible short-term damage do not establish efficacy or safety of Myelopid in patients. Individual peptides and mixtures must remain distinct.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Molecule. Defined myelopeptide-related sequences and their proposed immune applications; the patent does not validate every Myelopid preparation.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US6469137B1 ↗ · 2002-10-22
- Earliest priority / filing
- 1997-01-07 / 1998-01-07
- Original applicant / assignee
- Primamedic Ltd
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 10805577 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Myelopeptides and their therapeutic use
Inventors: Rem V. Petrov; Augusta A. Mikhailova; Larissa A. Fonina; Sergei A. Guriyanov.
US6469137B1 · US20030083236A1 · EP0960122A1 · JP2001508435A · AU728539B2 · CA2274731A1 · GB9700154D0 · NZ336243A · RU2198178C2 · WO1998030581A1
Study limitations and source details
Study limitations
- Patent efficacy proposals are not clinical evidence.
- Commercial product names require formulation-specific confirmation.
Source details
Selected original-source text checked; full methodological review pending.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
Author unconfirmed. Myelopeptides and their therapeutic use — US6469137B1 Primary source linked above